Financial Highlights for Quarter Ended March 31, 2026

  • Revenue: ₹58.45 crore
  • PAT (Profit After Tax): Loss of ₹4.98 crore
  • EPS (Earnings Per Share): Negative ₹4.82
  • EBITDA Margins: 2.28%
  • All figures are presented with quarter-on-quarter (Q-o-Q) and year-on-year (Y-o-Y) comparisons indicated by symbols, though specific comparative figures are not fully quantified in the provided data.

Financial Highlights for Year Ended March 31, 2026

  • Revenue: ₹187.20 crore, up 1% year-on-year
  • PAT (Profit After Tax): Loss of ₹24.66 crore
  • EPS (Earnings Per Share): Negative ₹23.84
  • EBITDA Margins: Negative 0.83%
  • The data indicates a significant year-on-year decline in profitability metrics.

Management Commentary by Mr. Sunil Mundra, Executive Director

Q4 FY26 Performance:

  • Q4 was a strong operational quarter. The company successfully dispatched goods that had been deferred in the prior quarter due to a shutdown at the Puducherry plant.
  • These deferred dispatches were the primary driver of growth in both topline and profitability during Q4.
  • The impact on the standalone capsules business was approximately ₹6 crore. These sales came at higher profitability as associated costs were absorbed in the previous quarter.

Capsules Business Update:

  • The incremental HPMC line for double-zero capsules is now ready.
  • Revenue from this new line is expected to begin in the second half of the current financial year (FY27), subject to client approval in the US markets.
  • FY27 is expected to be a stable year for the capsules business, with a focus on optimal capacity utilization and improving operational efficiency.

API Business Update:

  • Commercial sales for APIs commenced in Q4 FY26.
  • The focus is on gradually growing these volumes throughout the year.
  • The current API business carries a lower margin profile. The company is awaiting necessary clearances from regulatory authorities and customers to serve more profitable customers and geographies.

Subsidiary Update - Natural Biogenex Private Limited:

  • The subsidiary executed definitive Framework and Contract Manufacturing Agreements with Fermbox Bio Private Limited.
  • Under the collaboration, Fermbox Bio will provide advanced fermentation technology and equipment at Natural Capsules' Tumkur facility.
  • Natural Biogenex will undertake licensed manufacturing, quality assurance, and regulatory compliance.
  • This arrangement is expected to improve utilization of fermentation assets, create an additional revenue stream, and strengthen fermentation-based CDMO (Contract Development and Manufacturing Organization) capabilities.

Forward-Looking Strategy:

  • FY27 focus will be on scaling up operations in the API business while driving higher profitability in the capsules business.
  • The company enters FY27 with improved operational visibility and confidence in restoring growth and profitability.

Contacts for Further Information

  • Company Email: company.sec@naturalcapsules.com
  • Investor Relations Email: abhishek@theinvestmentlab.in
  • Company Representatives: Akshay Dutta (Natural Capsule Limited) and Abhishek Mehra (TIL Advisors Private Limited)

Forward-Looking Statement Disclaimer

The document contains forward-looking statements subject to risks and uncertainties including government actions, political or economic developments, and technological risks. The company undertakes no obligation to update these statements publicly.